Charles River Laboratories International, a Wilmington, Massachusetts-headquartered contract research organization (CRO), has agreed to acquire MPI Research, a Mattawan, Michigan-headquartered non-clinical contract research organization (CRO), for approximately $800 million.

MPI provides testing services to biopharmaceutical and medical device companies. Charles River says acquiring MPI will add to its ototoxicity and abuse liability capabilities, and expand Charles River’s existing capabilities in general toxicology and specialty toxicology, including ophthalmology, juvenile toxicity, molecular biology, and surgery, as well as medical device testing.

The transaction is expected to close early in the second quarter of 2018, subject to regulatory approvals and customary closing conditions. MPI is expected to be part of Charles River’s Discovery and Safety Assessment segment.

Source: Charles River Laboratories International